Amylyx Pharmaceuticals Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 136

Employees

  • Stock Symbol
  • AMLX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $30.28
  • (As of Friday Closing)

Amylyx Pharmaceuticals General Information

Description

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Contact Information

Website
www.amylyx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 55 Cambridge Parkway
  • Suite 6 West
  • Cambridge, MA 02142
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 55 Cambridge Parkway
  • Suite 6 West
  • Cambridge, MA 02142
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amylyx Pharmaceuticals Stock Performance

As of 13-Nov-2026, Amylyx Pharmaceuticals’s stock price is $30.28. Its current market cap is $3.89B with 129M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$30.28 $29.86 $10.83 - $41.14 $3.89B 129M 2.13M -$1.45

Amylyx Pharmaceuticals Financials Summary

As of 30-Sep-2026, Amylyx Pharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,406,925 988,565 27,283 643,584
Revenue 0 0 87,371 380,786
EBITDA (175,232) (153,466) (315,041) 39,230
Net Income (163,195) (144,735) (301,743) 49,271
Total Assets 786,795 332,645 193,634 517,454
Total Debt 4,943 5,957 1,981 4,237
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Amylyx Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amylyx Pharmaceuticals‘s full profile, request access.

Request a free trial

Amylyx Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Amylyx Pharmaceuticals‘s full profile, request access.

Request a free trial

Amylyx Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communit
Drug Discovery
Cambridge, MA
136 As of 2025

Cambridge, MA
 

New Haven, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amylyx Pharmaceuticals Competitors (9)

One of Amylyx Pharmaceuticals’s 9 competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
Biohaven Formerly VC-backed New Haven, CT
Apellis Pharmaceuticals Formerly VC-backed Waltham, MA
Aquinnah Venture Capital-Backed Cambridge, MA
Cognition Therapeutics Formerly VC-backed New York, NY
You’re viewing 5 of 9 competitors. Get the full list »

Amylyx Pharmaceuticals Patents

Amylyx Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026136695-A1 Liver x receptor agonists, compositions and methods Pending 20-Dec-2024
WO-2026122969-A1 Chi3l1-targeting oligonucleotides and methods of using the same Pending 06-Dec-2024
US-20260151460-A1 Treatment of post-bariatric hypoglycemia Pending 02-Dec-2024
WO-2026122473-A1 Treatment of post-bariatric hypoglycemia Pending 02-Dec-2024
WO-2026036030-A1 Antisense oligonucleotides targeting calpain-2 Pending 09-Aug-2024 C12N15/113
To view Amylyx Pharmaceuticals’s complete patent history, request access »

Amylyx Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amylyx Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Amylyx Pharmaceuticals‘s full profile, request access.

Request a free trial

Amylyx Pharmaceuticals Investments (1)

Amylyx Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Eiger BioPharmaceuticals (Patent Right of Avexitide) for . The deal was made on 09-Jul-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Eiger BioPharmaceuticals (Patent Right of Avexitide) 09-Jul-2024 Corporate Asset Purchase Buildings and Property
To view Amylyx Pharmaceuticals’s complete investments history, request access »

Amylyx Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.41 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Amylyx Pharmaceuticals’s complete esg history, request access »

Amylyx Pharmaceuticals FAQs

  • When was Amylyx Pharmaceuticals founded?

    Amylyx Pharmaceuticals was founded in 2013.

  • Where is Amylyx Pharmaceuticals headquartered?

    Amylyx Pharmaceuticals is headquartered in Cambridge, MA.

  • What is the size of Amylyx Pharmaceuticals?

    Amylyx Pharmaceuticals has 136 total employees.

  • What industry is Amylyx Pharmaceuticals in?

    Amylyx Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Amylyx Pharmaceuticals a private or public company?

    Amylyx Pharmaceuticals is a Public company.

  • What is Amylyx Pharmaceuticals’s stock symbol?

    The ticker symbol for Amylyx Pharmaceuticals is AMLX.

  • What is the current stock price of Amylyx Pharmaceuticals?

    As of 13-Nov-2026 the stock price of Amylyx Pharmaceuticals is $30.28.

  • What is the current market cap of Amylyx Pharmaceuticals?

    The current market capitalization of Amylyx Pharmaceuticals is $3.89B.

  • Who are Amylyx Pharmaceuticals’s competitors?

    Alnylam Pharmaceuticals, Biohaven, Apellis Pharmaceuticals, Aquinnah, and Cognition Therapeutics are some of the 9 competitors of Amylyx Pharmaceuticals.

  • What is Amylyx Pharmaceuticals’s annual earnings per share (EPS)?

    Amylyx Pharmaceuticals’s EPS for 12 months was -$1.45.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process